Cargando…

P1346: EVALUATION OF CURRENT NATIONAL PRACTICE IN THE PREVENTION OF PTLD POST PAEDIATRIC HSCT

Detalles Bibliográficos
Autores principales:	Kissane, E., Sulevani, I., James, D. B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429455/ http://dx.doi.org/10.1097/01.HS9.0000848248.97940.53

Ejemplares similares

P1346: THE IMPACT OF CYTOTOXIC THERAPY ON THE RISK OF PROGRESSION AND DEATH IN PATIENTS WITH CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE.
por: Marissa, LI, et al.
Publicado: (2023)

1346 Flutisane Propionate in Prevention of Rhynitis Alergica with Children
por: Timovski, I, et al.
Publicado: (2010)

1346. Implementation of a Multidisciplinary 48 Hour Antibiotic Timeout in a Pediatric Population
por: Konold, Victoria, et al.
Publicado: (2020)

Biological Warfare at the 1346 Siege of Caffa
por: Wheelis, Mark
Publicado: (2002)

A case of post renal transplant PTLD of lung
por: Sinha, Tanay, et al.
Publicado: (2023)

Book Review: The Black Death 1346–1353: the complete history
por: Christensen, Peter
Publicado: (2006)

P1388: EFFECTIVENESS AND SAFETY OUTCOMES IN PATIENTS WITH EBV+ PTLD TREATED WITH ALLOGENEIC EBV-SPECIFIC T-CELL IMMUNOTHERAPY (TABELECLEUCEL) UNDER AN EXPANDED ACCESS PROGRAM IN EUROPE
por: Choquet, Sylvain, et al.
Publicado: (2023)

P1339: CLINICAL OUTCOMES OF PATIENTS WITH EBV+ PTLD FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION WHO FAIL RITUXIMAB: A MULTINATIONAL, RETROSPECTIVE CHART REVIEW STUDY
por: Sanz-Caballer, J., et al.
Publicado: (2022)

P1107: CLINICAL OUTCOMES OF SOLID ORGAN TRANSPLANT PATIENTS WITH EBV+ PTLD WHO FAIL RITUXIMAB PLUS CHEMOTHERAPY: A MULTINATIONAL, RETROSPECTIVE CHART REVIEW STUDY
por: Dharnidharka, V., et al.
Publicado: (2022)

Post-transplant lymphoproliferative disorder (PTLD): single institutional experience of 141 patients
por: Bishnoi, Rohit, et al.
Publicado: (2017)

POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (PTLD) IN RENAL TRANSPLANT PATIENTS WITH COVID-19
por: MAHONEY, IAN, et al.
Publicado: (2022)

P1457: DEMOGRAPHICS AND TREATMENT OUTCOMES IN PATIENTS WITH EBV+ PTLD TREATED WITH OFF-THE-SHELF EBV-SPECIFIC CTL (TABELECLEUCEL) UNDER AN ONGOING EXPANDED ACCESS PROGRAM IN EUROPE: FIRST ANALYSES
por: Choquet, S., et al.
Publicado: (2022)

O01 Post-transplant lymphoproliferative disorder (PTLD) in a patient with rheumatoid arthritis
por: Kim, Sung-Hee, et al.
Publicado: (2021)

P1326: FACTORS ASSOCIATED WITH THE OUTCOME OF ALLO-HSCT FOR ADVERSE-CYTOGENETIC RISK ACUTE MYELOID LEUKEMIA
por: Cerezo-Martin, J. M., et al.
Publicado: (2022)

PD‐L1 and PD1 expression in post‐transplantation lymphoproliferative disease (PTLD) of childhood and adolescence: An inter‐ and intra‐individual descriptive study covering the whole spectrum of PTLD categories
por: Schiefer, Ana‐Iris, et al.
Publicado: (2019)

HLA-E–restricted immune responses are crucial for the control of EBV infections and the prevention of PTLD
por: Vietzen, Hannes, et al.
Publicado: (2023)

P837: ELTROMBOPAG (EPAG) INDUCES HEMATOLOGIC RESPONSES FOR PATIENTS WITH POST-ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANT POOR GRAFT FUNCTION (POST-ALLO HSCT PGF): RESULTS OF THE ELTION STUDY IN SPAIN
por: Vallejo, C., et al.
Publicado: (2022)

1411. Risks and Outcomes of Adenovirus Disease in Pediatric HSCT Recipients –Comparison of Current Antiviral Treatment Options
por: Thomas, Sanya J, et al.
Publicado: (2020)

Post-transplant Lymphoproliferative Disorder (PTLD) in the US Population: Demographics, Treatment Characteristics, and Survival Analysis
por: Ullah, Asad, et al.
Publicado: (2023)

P1394: DIFFERENT DOSES OF ANTITHYMOCYTE GLOBULIN (ATG) AS PART OF THE PREPARATIVE REGIMEN IN HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
por: Zhou, S., et al.
Publicado: (2022)

P47 The conundrums of Macrophage activation syndrome (MAS) - when to consider a Haematopoietic Stem Cell Transplant (HSCT)
por: Gallagher, Kathy, et al.
Publicado: (2022)

P1390: NEW AND UPDATED RESULTS FROM A MULTICENTER OPEN-LABEL GLOBAL PHASE3 STUDY OF TAB-CEL FOR EBV+PTLD FOLLOWING HCT OR SOT AFTER FAILURE OF RITUXIMAB OR RITUXIMAB+CHEMOTHERAPY (ALLELE)
por: Kris Michael, Mahadeo, et al.
Publicado: (2023)

P037 Home spirometry engagement in a paediatric network post pandemic
por: Lawrence, P., et al.
Publicado: (2023)

PTLD Burkitt Lymphoma in a Patient with Remote Lymphomatoid Granulomatosis
por: Stravodimou, A., et al.
Publicado: (2012)

P1330: IMPACT OF COVID-19 IN HSCT ACTIVITY. A SURVEY FROM THE INFECTIOUS DISEASES WORKING PARTY (IDWP) OF EBMT
por: De La Camara, R., et al.
Publicado: (2022)

P570: VENETOCLAX PLUS HYPOMETHYLATING AGENTS VERSUS INTENSIVE CHEMOTHERAPY FOR HEMATOLOGICAL RELAPSE OF MYELOID MALIGNANCIES AFTER ALLO-HSCT
por: Chen, Zhangjie, et al.
Publicado: (2023)

P-040: RED BLOOD CELLS ADHESION AND OCCLUSION INDEX IN A PATIENT WITH SICKLE CELL DISEASE PRIOR AND POST HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)
por: K., MINCHAMP, et al.
Publicado: (2022)

1346. Genetic Variation at the Interferon λ Locus and Association with Clinical Outcome and Severity of COVID-19
por: Alalwan, Dana, et al.
Publicado: (2023)

P390: ALLO-HSCT OR CHEMOTHERAPY FOR B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA IN THE FIRST COMPLETE REMISSION: IMPACT OF MRD AND IKZF1
por: Deng, Shiyu, et al.
Publicado: (2023)

P1572: COVID-19 MORTALITY IN HIGH-RISK PATIENTS AFTER ALLO-HSCT AND CAR-T: IMPROVED OUTCOME THROUGH A PANDEMIC.
por: Sannipoli, Daniele, et al.
Publicado: (2023)

P1324: EFFICACY AND SAFETY OF DOSE-ADJUSTED ATG COMBINED WITH CD25 ANTIBODY IN THE PREVENTION OF GVHD AFTER HAPLO-HSCT: CLINICAL STUDY DATA FROM A SINGLE CENTER IN CHINA
por: Zhu, Lidan, et al.
Publicado: (2023)

P1528: DIAGNOSTIC AND THERAPEUTIC EVALUATION OF CARBAPENEM-RESISTANT ORGANISMS BLOODSTREAM INFECTION FROM GUT COLONIZATION IN HSCT PATIENTS UNDERWENT CARBAPENEMASE GENES GUIDED THERAPY
por: Chenjing, Qian, et al.
Publicado: (2023)

Management of PTLD After Hematopoietic Stem Cell Transplantation: Immunological Perspectives
por: Compagno, Francesca, et al.
Publicado: (2020)

Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial
por: Zimmermann, Heiner, et al.
Publicado: (2022)

Post-Transplant Lymphoproliferative Disease (PTLD) after Allogeneic Hematopoietic Stem Cell Transplantation: Biology and Treatment Options
por: Clerico, Michele, et al.
Publicado: (2022)

P1417: PROPHYLACTIC NAC PROMOTED HEMATOPOIETIC RECONSTITUTION BY IMPROVING ENDOTHELIAL CELLS AFTER HSCT: A PHASE 3, OPEN-LABEL RANDOMIZED TRIAL
por: Wang, Y., et al.
Publicado: (2022)

P1322: ALLOGENEIC HEMATOPOIETIC STEM TRANSPLANTATION (HSCT) IN PATIENTS OVER 60 YEARS. RETROSPECTIVE EXPERIENCE OF TWO SPANISH CENTERS BETWEEN 2015-2020
por: Baile González, M., et al.
Publicado: (2022)

P1298: THE EFFICACY AND SAFETY OF MODIFIED MELPHALAN AND BUSULFAN-BASED CONDITIONING REGIMEN FOR ALLOGENEIC-HSCT IN REFRACTORY/RELAPSED OR PERSISTENT MRD POSITIVITY AML PATIENTS
por: Jiang, Erlie, et al.
Publicado: (2023)

P1253: REDUCED EXPRESSION OF THE CHEMOKINES CXCL2, CXCL3 AND CXCL8 PROVIDES A POTENTIAL MECHANISM PROMOTING IMMUNE EVASION FACILITATING AML RELAPSE FOLLOWING ALLOGENEIC HSCT
por: Charrot, Sarah, et al.
Publicado: (2023)

Chimeric antigen receptor (CAR) T cells for the treatment of a kidney transplant patient with post-transplant lymphoproliferative disorder (PTLD)
por: Kline, Kathryn, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fkgrsj4vq9qpfgjot5ge0fo6m7